TC-002, a latanoprost ophthalmic solution, met all primary and secondary endpoints in the phase 3 CLEAR pivotal trial, according to a press release from TearClear.
TC-002 contains benzalkonium chloride while it is in the bottle to maintain sterility, increase stability and aid in solubility, but the preservative is removed from the drops as they are dispensed in the eye, reducing the prevalence of signs and symptoms of ocular surface disease that can be caused by drops with preservatives.
The glaucoma drug met the primary efficacy endpoint of difference in mean change from baseline in IOP at